Literature DB >> 7391983

Controlled delivery of an antitumor drug: localized action of liposome encapsulated cytosine arabinoside administered via the respiratory system.

R L Juliano, H N McCullough.   

Abstract

Cytosine arabinoside in free or liposome encapsulated form was administered to the lungs of rats via intratracheal instillation. The free drug rapidly left the lung (T 1/2 = 40 min), while the encapsulated drug remained in the lung for a prolonged period (T 1/2 = 8 hr). Free cytosine arabinoside effectively inhibited DNA synthesis (measured by [14C]thymidine incorporation) in the intestine and bone marrow as well as in the lung. By contrast, liposome-encapsulated drug effectively inhibited DNA synthesis in the lung, but similar doses failed to inhibit DNA synthesis in other tissues. The metabolism of free and encapsulated drug were similar in that the same products resulted, namely the inactive catabolite uracil-beta-D-arabinofuranoside and the phosphorylated anabolites of cytoside arabinoside. These results suggest that the action of an antitumor drug can be confined to a single organ through the use of a liposomal drug delivery system.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7391983

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  Iloprost-containing liposomes for aerosol application in pulmonary arterial hypertension: formulation aspects and stability.

Authors:  Elke Kleemann; Thomas Schmehl; Tobias Gessler; Udo Bakowsky; Thomas Kissel; Werner Seeger
Journal:  Pharm Res       Date:  2006-12-27       Impact factor: 4.200

2.  Incorporation of the antitumor alkaloid thaliblastine in liposomes enhances its cytotoxic activity in vitro.

Authors:  D K Todorov; G Deliconstantinos
Journal:  Experientia       Date:  1982-07-15

3.  The influence of liposomal encapsulation on sodium cromoglycate pharmacokinetics in man.

Authors:  K M Taylor; G Taylor; I W Kellaway; J Stevens
Journal:  Pharm Res       Date:  1989-07       Impact factor: 4.200

4.  Nebulization of liposomes. I. Effects of lipid composition.

Authors:  R W Niven; H Schreier
Journal:  Pharm Res       Date:  1990-11       Impact factor: 4.200

5.  Pulmonary absorption of liposomal levonorgestrel.

Authors:  Aliasgar Shahiwala; Ambikanandan Misra
Journal:  AAPS PharmSciTech       Date:  2004-03-04       Impact factor: 3.246

Review 6.  Liposomes as carriers of cancer chemotherapy. Current status and future prospects.

Authors:  S Kim
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

7.  Solute absorption from the airways of the isolated rat lung. II. Effect of surfactants on absorption of fluorescein.

Authors:  R W Niven; P R Byron
Journal:  Pharm Res       Date:  1990-01       Impact factor: 4.200

8.  Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa.

Authors:  A Omri; C Beaulac; M Bouhajib; S Montplaisir; M Sharkawi; J Lagacé
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

9.  Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery.

Authors:  Xiaoyu Chen; Wenhua Huang; Blenda Chi Wong; Linlin Yin; Yuen Fan Wong; Min Xu; Zhijun Yang
Journal:  Int J Nanomedicine       Date:  2012-02-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.